These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 26964144)

  • 21. Biosimilars in rheumatology: perspective and concerns.
    Scheinberg MA; Azevedo VF
    Rheumatology (Oxford); 2014 Mar; 53(3):389-90. PubMed ID: 23878310
    [No Abstract]   [Full Text] [Related]  

  • 22. Potential for biosimilars in rheumatology in Africa.
    Abu-Zaid MH; Adebajo A; El Miedany Y
    Ann Rheum Dis; 2023 Dec; 82(12):1508-1510. PubMed ID: 37468221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The road from development to approval: evaluating the body of evidence to confirm biosimilarity.
    Declerck P; Farouk Rezk M
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv4-iv13. PubMed ID: 28903545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilars for the management of rheumatoid arthritis: economic considerations.
    Gulácsi L; Brodszky V; Baji P; Kim H; Kim SY; Cho YY; Péntek M
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S43-52. PubMed ID: 26395836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current state of biosimilars in Mexico: The position of the Mexican College of Rheumatology, 2016.
    Xibille D; Carrillo S; Huerta-Sil G; Hernández R; Limón L; Olvera-Soto G; Jara-Quezada LJ; Esquivel A; Pérez-Rodríguez M
    Reumatol Clin (Engl Ed); 2018; 14(3):127-136. PubMed ID: 28807650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of biosimilars in the treatment of rheumatic diseases.
    Dörner T; Strand V; Castañeda-Hernández G; Ferraccioli G; Isaacs JD; Kvien TK; Martin-Mola E; Mittendorf T; Smolen JS; Burmester GR
    Ann Rheum Dis; 2013 Mar; 72(3):322-8. PubMed ID: 23253920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-TNF biosimilars in rheumatology: the end of an era?
    Dey M; Zhao SS; Moots RJ
    Expert Opin Biol Ther; 2021 Jan; 21(1):29-36. PubMed ID: 32735158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Biologics and Biosimilars in Rheumatology.
    Sharma SK
    J Assoc Physicians India; 2017 May; 65(5 Suppl):9-14. PubMed ID: 28836745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.
    Gulácsi L; Brodszky V; Baji P; Rencz F; Péntek M
    Adv Ther; 2017 May; 34(5):1128-1144. PubMed ID: 28397080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biosimilars: how similar?
    Strand V; Cronstein B
    Intern Med J; 2014 Mar; 44(3):218-23. PubMed ID: 24118772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilars in pediatric rheumatology and their introduction into routine care.
    Aragon Cuevas O; Hedrich CM
    Clin Immunol; 2020 Jul; 216():108447. PubMed ID: 32360950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Portuguese Society of Rheumatology position paper on the use of biosimilars.
    Fonseca JE; Gonçalves J; Araújo F; Cordeiro I; Teixeira F; Canhão H; da Silva JA; Garcês S; Miranda LC; Ramiro S; Roxo A; Pimentel-Santos FM; Tavares V; Neto A; Sepriano A; Malcata A; Faustino A; Silva C; Ambrósio C; Duarte C; Miguel C; Barcelos F; Santos H; Cunha I; Ramos JC; Gomes JA; Pimentão JB; Costa L; Maurício L; Silva M; Bernardes M; Bogas M; Coelho PC; Monteiro P; Aguiar R; André R; Leitão R; Pimenta S; Meirinhos T; Fernandes S; Las V; Castelão W;
    Acta Reumatol Port; 2014; 39(1):60-71. PubMed ID: 24811463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Biosimilars].
    Burmester GR; Müller-Ladner U
    Z Rheumatol; 2015 Oct; 74(8):670-1. PubMed ID: 26450433
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI).
    Schaeverbeke T; Pham T; Richez C; Wendling D
    Joint Bone Spine; 2018 Jul; 85(4):399-402. PubMed ID: 29574143
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?
    Araújo FC; Gonçalves J; Fonseca JE
    Curr Rheumatol Rep; 2016 Aug; 18(8):50. PubMed ID: 27402107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases.
    Gils A; Bertolotto A; Mulleman D; Bejan-Angoulvant T; Declerck PJ
    Ther Drug Monit; 2017 Aug; 39(4):308-315. PubMed ID: 28230618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The future landscape of biosimilars in rheumatology: Where we are where we are going.
    Scheinberg M; Azevedo V
    Autoimmun Rev; 2019 Feb; 18(2):203-208. PubMed ID: 30572130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.